Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735646 | 1.00 | HCAR2 (0.35) | HCAR2KEAP1NFE2L2OXER1EPHX1 | |
| SCHEMBL30117374 | 0.83 | TAS1R3 (0.39) | HCAR2KEAP1NFE2L2OXER1TAS1R3 | |
| SCHEMBL22811569 | 0.81 | OXER1 (0.35) | HCAR2KEAP1NFE2L2OXER1EPHX1 | |
| SCHEMBL5411842 | 0.78 | ALDH1A1 (0.37) | HCAR2OXER1TAS1R3TAS1R1CNR1 | |
| SCHEMBL5411837 | 0.78 | ALDH1A1 (0.37) | HCAR2OXER1TAS1R3TAS1R1CNR1 | |
| SCHEMBL14488940 | 0.76 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2EPHX1ALDH1A1 | |
| SCHEMBL13001788 | 0.74 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2EPHX1ALDH1A1 | |
| SCHEMBL690239 | 0.73 | — | — | |
| SCHEMBL20877837 | 0.73 | — | — | |
| SCHEMBL239571 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008059051-A1 | SYNTHESIS OF IMIDE COMPOUNDS | PPG INDUSTRIES, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059051-A1 | SYNTHESIS OF IMIDE COMPOUNDS | PPG INDUSTRIES, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-7351849-B2 | Process for producing optically active β-amino acid derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20060205968-A1 | Process for producing optically active beta-amino acid derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1656342-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-AMINO ACID DERIVATIVES | Takasago International Corporation (JP) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005016866-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIIVE BETA-AMINO ACID DERIVATIVES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205968-A1 | Process for producing optically active beta-amino acid derivatives | BCAT1, ALAD, AADAT | HCAR2 375/4885KEAP1 2295/4885NFE2L2 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.